PRMT2 was able to reverse tamoxifen resistance in breast cancer cells generated by ER-α36, an estrogen receptor isoform lacking transcription activation functions AF-1 and AF-2 but still containing the DNA-binding domain and most of the hormone-binding domain [60]. Here, PRMT2 is linked to breast cancer.